Primrose J N, Rogers M J, Holmfield J H
Department of Clinical Medicine, The University, Leeds, UK.
Aliment Pharmacol Ther. 1993 Jun;7(3):287-91. doi: 10.1111/j.1365-2036.1993.tb00100.x.
The aim of this study was to compare to placebo the effects of 300 mg ranitidine nocte, b.d. and q.d. on intragastric acidity. The study was performed on healthy male subjects and intragastric acidity measured by radiotelemetry. All active treatments significantly decreased 24-hr acidity, with a median suppression of 61.0% with 300 mg ranitidine nocte, 77.7% with 300 mg b.d. and 78.0% with 300 mg q.d.s. There was no significant difference between the effects of two higher dose regimens; although the 300 mg q.d.s. suppressed daytime acidity more than 300 mg b.d. (88.9% vs. 77.8%), it suppressed nocturnal acidity less effectively (65.5%) than either 300 mg nocte (92.9%) or 300 mg b.d. (90.0%). These data suggest that only modest additional therapeutic acid inhibition can be achieved by increasing the dose of ranitidine above 600 mg daily.
本研究旨在比较每晚一次、每日两次及每日一次服用300毫克雷尼替丁相对于安慰剂对胃内酸度的影响。该研究在健康男性受试者身上进行，通过无线电遥测法测量胃内酸度。所有活性治疗均显著降低了24小时酸度，每晚一次服用300毫克雷尼替丁的中位抑制率为61.0%，每日两次服用300毫克的为77.7%，每日一次服用300毫克的为78.0%。两种较高剂量方案的效果之间无显著差异；尽管每日一次服用300毫克对白天酸度的抑制作用大于每日两次服用300毫克（88.9%对77.8%），但其对夜间酸度的抑制效果（65.5%）不如每晚一次服用300毫克（92.9%）或每日两次服用300毫克（90.0%）有效。这些数据表明，将雷尼替丁剂量增加至每日600毫克以上仅能实现适度的额外治疗性胃酸抑制。
